Strategic Partners | Gerontological Advanced Practice Nurses Association (GAPNA)

We offer customizable partnership opportunities to meet your corporate goals, whether it’s brand visibility, thought leadership, or community engagement.

View complete details about the GAPNA Strategic Partners Program.

If you’re ready to elevate your partnership with GAPNA, contact Meghan Cash at meghan.cash@ajj.com or call 856-256-2374. Together, we’ll create a package that aligns with your organization’s goals and delivers maximum value.

GAPNA thanks our Strategic Partners for their support of our organization.

Eisai
6611 Tributary Street, Suite 1
Baltimore, MD 21224
410-631-6300
www.eisai.com

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.

Neurocrine Biosciences Inc.
12780 El Camino Real
San Diego, CA 92130
858-617-7600
www.neurocrine.com

Neurology and Endocrinology Research and Therapy | Neurocrine Biosciences

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com.

Additional Resources on Tardive Dyskinesia

Otsuka
508 Carnegie Center Dr,
Princeton, NJ 08540
609-524-6788
www.otsuka-us.com

We place greater value on what we can achieve together than on what we can do alone because the needs of those we serve always come first. We will not be bound by doing what’s been done before. Instead, we free ourselves from preconceived notions to discover solutions that advance patient care. Our mission is clear: Otsuka-people, creating new products for better health worldwide.

Additional Resources on Agitation in Alzheimer’s Disease

Sumitomo Pharma America, Inc.
84 Waterford Drive
Marlborough, MA 01752
phone: 508-481-6700
www.us.sumitomo-pharma.com

Sumitomo Pharma America (SMPA) is focused on addressing patient needs in oncology, urology, women's health, rare diseases, psychiatry & neurology, and cell & gene therapies. With several marketed products in the U.S., Canada, and Europe, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner.

SMPA was formed through the consolidation of Sumitomo Pharma’s U.S. affiliates. Our parent company, the Sumitomo Group, is over 400 years old, with an extensive history of supporting health and wellbeing. SMPA is a Sumitomo Pharma company.

Acadia Pharmaceuticals Inc.
12830 El Camino Real, Suite 400
San Diego, CA 92130
844-422-2342
https://acadia.com/en-us

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.

www.alphacognition.com/

Alpha Cognition is a biopharmaceutical company dedicated to developing innovative therapies for patients suffering from neurodegenerative diseases. Our mission is to enhance the quality of life for patients and caregivers by delivering safe, effective, and accessible treatments that address significant unmet needs in neurology.

Our portfolio includes ZUNVEYL®️(Benzgalantamine), an FDA-approved treatment for mild to moderate Alzheimer’s disease, which is also being investigated for cognitive impairment associated with mild traumatic brain injury (mTBI). With over 30 years of collective drug discovery and commercialization experience, our leadership team applies a science-first, patient-focused approach—combining cutting-edge research with a deep understanding of real-world care environments.

We are proud to be one of the few companies actively prioritizing solutions for long-term care settings, supporting both healthcare providers and the residents they serve. Our strategy blends innovation with compassion, ensuring that new scientific breakthroughs are guided by the people and communities who need them most.

At Alpha Cognition, we believe meaningful progress happens where science meets compassion.

Learn more: alphacognition.com
Follow us: Twitter | LinkedIn

100 Morris St. Morristown, NJ 07960

www.sanofi.com

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.